Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer

Michael D. Toboni; Elena Lomonosova; Shaina F. Bruce; Jo’An I. Tankou; Mary M. Mullen; Angela Schab; Alyssa Oplt; Hollie Noia; Danny Wilke; Lindsay M. Kuroki; Andrea R. Hagemann; Carolyn K. McCourt; Premal H. Thaker; Matthew A. Powell; Dineo Khabele; David G. Mutch; Katherine C. Fuh

doi:10.3390/cancers13235877

Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer

Michael D. Toboni, Elena Lomonosova, Shaina F. Bruce, Jo’An I. Tankou, Mary M. Mullen, Angela Schab, Alyssa Oplt, Hollie Noia, Danny Wilke, Lindsay M. Kuroki, Andrea R. Hagemann, Carolyn K. McCourt, Premal H. Thaker, Matthew A. Powell, Dineo Khabele, David G. Mutch, Katherine C. Fuh

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Endometrial cancer remains the most prevalent gynecologic cancer with continued rising incidence. A less common form of this cancer is uterine serous cancer, which represents 10% of endometrial cancer cases. However, this is the most aggressive cancer. The objective was to assess whether inhibiting the receptor tyrosine kinase AXL with AVB‐500 in combination with bevacizumab would improve response in uterine serous cancer. To prove this, we conducted multiple angiogenesis assays including tube formation assays and angiogenesis invasion assays. In addition, we utilized mouse models with multiple cells lines and subsequently analyzed harvested tissue through immunohistochemistry CD31 staining to assess microvessel density. The combination treatment arms demonstrated decreased angiogenic potential in each assay. In addition, intraperitoneal mouse models demonstrated a significant decrease in tumor burden in two cell lines. The combination of AVB‐500 and bevacizumab reduced tumor burden in vivo and reduced morphogenesis and migration in vitro which are vital to the process of angiogenesis.

Original language	English (US)
Article number	5877
Journal	Cancers
Volume	13
Issue number	23
DOIs	https://doi.org/10.3390/cancers13235877
State	Published - Dec 2021

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13235877

Cite this

Toboni, M. D., Lomonosova, E., Bruce, S. F., Tankou, JA. I., Mullen, M. M., Schab, A., Oplt, A., Noia, H., Wilke, D., Kuroki, L. M., Hagemann, A. R., McCourt, C. K., Thaker, P. H., Powell, M. A., Khabele, D., Mutch, D. G., & Fuh, K. C. (2021). Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer. Cancers, 13(23), Article 5877. https://doi.org/10.3390/cancers13235877

@article{35d4a7a85769402280647b28674b9f23,

title = "Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer",

abstract = "Endometrial cancer remains the most prevalent gynecologic cancer with continued rising incidence. A less common form of this cancer is uterine serous cancer, which represents 10% of endometrial cancer cases. However, this is the most aggressive cancer. The objective was to assess whether inhibiting the receptor tyrosine kinase AXL with AVB‐500 in combination with bevacizumab would improve response in uterine serous cancer. To prove this, we conducted multiple angiogenesis assays including tube formation assays and angiogenesis invasion assays. In addition, we utilized mouse models with multiple cells lines and subsequently analyzed harvested tissue through immunohistochemistry CD31 staining to assess microvessel density. The combination treatment arms demonstrated decreased angiogenic potential in each assay. In addition, intraperitoneal mouse models demonstrated a significant decrease in tumor burden in two cell lines. The combination of AVB‐500 and bevacizumab reduced tumor burden in vivo and reduced morphogenesis and migration in vitro which are vital to the process of angiogenesis.",

author = "Toboni, {Michael D.} and Elena Lomonosova and Bruce, {Shaina F.} and Tankou, {Jo{\textquoteright}An I.} and Mullen, {Mary M.} and Angela Schab and Alyssa Oplt and Hollie Noia and Danny Wilke and Kuroki, {Lindsay M.} and Hagemann, {Andrea R.} and McCourt, {Carolyn K.} and Thaker, {Premal H.} and Powell, {Matthew A.} and Dineo Khabele and Mutch, {David G.} and Fuh, {Katherine C.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = dec,

doi = "10.3390/cancers13235877",

language = "English (US)",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "23",

}

TY - JOUR

T1 - Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer

AU - Toboni, Michael D.

AU - Lomonosova, Elena

AU - Bruce, Shaina F.

AU - Tankou, Jo’An I.

AU - Mullen, Mary M.

AU - Schab, Angela

AU - Oplt, Alyssa

AU - Noia, Hollie

AU - Wilke, Danny

AU - Kuroki, Lindsay M.

AU - Hagemann, Andrea R.

AU - McCourt, Carolyn K.

AU - Thaker, Premal H.

AU - Powell, Matthew A.

AU - Khabele, Dineo

AU - Mutch, David G.

AU - Fuh, Katherine C.

PY - 2021/12

Y1 - 2021/12

N2 - Endometrial cancer remains the most prevalent gynecologic cancer with continued rising incidence. A less common form of this cancer is uterine serous cancer, which represents 10% of endometrial cancer cases. However, this is the most aggressive cancer. The objective was to assess whether inhibiting the receptor tyrosine kinase AXL with AVB‐500 in combination with bevacizumab would improve response in uterine serous cancer. To prove this, we conducted multiple angiogenesis assays including tube formation assays and angiogenesis invasion assays. In addition, we utilized mouse models with multiple cells lines and subsequently analyzed harvested tissue through immunohistochemistry CD31 staining to assess microvessel density. The combination treatment arms demonstrated decreased angiogenic potential in each assay. In addition, intraperitoneal mouse models demonstrated a significant decrease in tumor burden in two cell lines. The combination of AVB‐500 and bevacizumab reduced tumor burden in vivo and reduced morphogenesis and migration in vitro which are vital to the process of angiogenesis.

AB - Endometrial cancer remains the most prevalent gynecologic cancer with continued rising incidence. A less common form of this cancer is uterine serous cancer, which represents 10% of endometrial cancer cases. However, this is the most aggressive cancer. The objective was to assess whether inhibiting the receptor tyrosine kinase AXL with AVB‐500 in combination with bevacizumab would improve response in uterine serous cancer. To prove this, we conducted multiple angiogenesis assays including tube formation assays and angiogenesis invasion assays. In addition, we utilized mouse models with multiple cells lines and subsequently analyzed harvested tissue through immunohistochemistry CD31 staining to assess microvessel density. The combination treatment arms demonstrated decreased angiogenic potential in each assay. In addition, intraperitoneal mouse models demonstrated a significant decrease in tumor burden in two cell lines. The combination of AVB‐500 and bevacizumab reduced tumor burden in vivo and reduced morphogenesis and migration in vitro which are vital to the process of angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85119625999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119625999&partnerID=8YFLogxK

U2 - 10.3390/cancers13235877

DO - 10.3390/cancers13235877

M3 - Article

AN - SCOPUS:85119625999

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 23

M1 - 5877

ER -

Inhibition of axl and vegf‐a has improved therapeutic efficacy in uterine serous cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this